Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 3, Mars 2008
Page(s) 306 - 313
Section M/S revues
DOI https://doi.org/10.1051/medsci/2008243306
Publié en ligne 15 mars 2008
  1. Leclerc C. L’apport des nouvelles technologies en vaccinologie. Med Sci (Paris) 2007; 23 : 386–90.
  2. Zagury D, Le Buanec H, Bizzini B, et al. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 2003; 14 : 123–37.
  3. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID Aids vaccine clinical trials network. JAMA 1994; 272 : 475–80.
  4. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007; 30 : 116–22.
  5. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 : 1915–27.
  6. Orenstein JM, Preble OT, Kind P, Schulof R. The relationship of serum alpha-interferon and ultrastructural markers in HIV-seropositive individuals. Ultrastruct Pathol 1987; 11 : 673–9.
  7. Badou A, Bennasser Y, Moreau M, et al. Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 2000; 74 : 10551–62.
  8. Kekow J, Wachsman W, McCutchan JA, et al. Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 1990; 87 : 8321–5.
  9. Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 1999; 96 : 8324–6.
  10. Le Buanec H, D’Anna R, Lachgar A, et al. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed Pharmacother 1999; 53 : 424–31.
  11. D’Anna R, Le Buanec H, Alessandri G, et al. Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoprotein. J Natl Cancer Inst 2001; 93 : 1843–51.
  12. Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000; 83 : 887–91.
  13. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005; 435 : 612–9.
  14. Le Buanec H, Delavallee L, Bessis N, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006; 103 : 19442–7.
  15. Bizzini B, Achour A. « Kinoids »: the basis for anticytokine immunization and their use in HIV infection. Cell Mol Biol 1995; 41 : 351–6.
  16. Sabbatini PJ, Kudryashov V, Ragupathi G, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 2000; 87 : 79–85.
  17. Lamm DL, Dehaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 2000; 37 (suppl 3) : 41–4.
  18. Richard M, Grencis RK, Humphreys NE, et al. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci USA 2000; 97 : 767–72.
  19. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36 : 2868–74.
  20. Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002; 169 : 6120–6.
  21. Galle P, Hougs L, Barington T, et al. Knocking out IL-6 by vaccination. Eur J Immunol 2004; 34 : 291–300.
  22. Spohn G, Guler R, Johansen P, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007; 178 : 7450–7.
  23. Chensue SW, Terebuh PD, Remick DG, et al. In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. Am J Pathol 1991; 138 : 395–402.
  24. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000; 68 : 455–63.
  25. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1 infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20 : 358–70.
  26. Rad FH, Le Buanec H, Paturance S, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 2007; 104 : 2837–42.
  27. Le Buanec H, Paturance S, Couillin I, et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 2007; 25 : 7206–16.
  28. Raaberg L, Nexo E, Jorgensen PE, et al. Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor. Pediatr Res 1995; 37 : 175–81.
  29. Svenson M, Hansen MB, Thomsen AR, et al. Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. J Immunol Methods 2000; 236 : 1–8.
  30. Gonzalez G, Crombet T, Catala M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9 : 431–5.
  31. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344 : 1105–10.
  32. Den Broeder A, Van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29 : 2288–98.
  33. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340 : 253–9.
  34. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21 : 60–5.
  35. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005; 34 : 19–22.
  36. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005; 329–34.
  37. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4 : 4 23–36.
  38. Silbermann B, Launay O. Prévention des infections à papillomavirus et du zona : nouveaux vaccins. Med Sci (Paris) 2007; 23 : 423–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.